Neurocrine Biosciences' (NBIX) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Neurocrine Biosciences (NASDAQ:NBIX - Free Report) in a research report report published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $155.00 price target on the stock.

Several other brokerages have also recently issued reports on NBIX. StockNews.com upgraded shares of Neurocrine Biosciences from a buy rating to a strong-buy rating in a research report on Thursday, February 8th. Citigroup lowered their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a neutral rating for the company in a research note on Thursday, February 8th. Wells Fargo & Company lifted their price target on Neurocrine Biosciences from $127.00 to $140.00 and gave the company an equal weight rating in a research report on Thursday, February 8th. The Goldman Sachs Group increased their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a buy rating in a report on Thursday, January 25th. Finally, Barclays boosted their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $139.25.

Neurocrine Biosciences Trading Down 0.6 %

NASDAQ NBIX traded down $0.85 on Wednesday, hitting $138.09. The company's stock had a trading volume of 639,131 shares, compared to its average volume of 858,210. The firm has a market cap of $13.74 billion, a P/E ratio of 57.06, a PEG ratio of 0.90 and a beta of 0.25. Neurocrine Biosciences has a 52-week low of $89.04 and a 52-week high of $148.37. The company's 50-day simple moving average is $136.96 and its 200 day simple moving average is $126.05.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm's revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. On average, research analysts forecast that Neurocrine Biosciences will post 4.83 EPS for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $139.86, for a total value of $1,398,600.00. Following the transaction, the insider now directly owns 35,882 shares in the company, valued at $5,018,456.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $139.86, for a total transaction of $1,398,600.00. Following the transaction, the insider now directly owns 35,882 shares of the company's stock, valued at approximately $5,018,456.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Charles Gorman sold 2,707 shares of the business's stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the transaction, the chief executive officer now owns 502,188 shares of the company's stock, valued at $70,652,829.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 177,176 shares of company stock worth $24,562,081. 4.60% of the stock is owned by company insiders.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently modified their holdings of NBIX. BlackRock Inc. raised its stake in Neurocrine Biosciences by 6.6% during the 1st quarter. BlackRock Inc. now owns 13,466,650 shares of the company's stock valued at $1,363,094,000 after purchasing an additional 838,997 shares during the period. Vanguard Group Inc. raised its position in shares of Neurocrine Biosciences by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company's stock valued at $1,279,433,000 after buying an additional 150,485 shares during the last quarter. State Street Corp raised its position in shares of Neurocrine Biosciences by 4.1% during the second quarter. State Street Corp now owns 3,956,499 shares of the company's stock valued at $373,098,000 after buying an additional 156,584 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Neurocrine Biosciences by 25.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,476,949 shares of the company's stock worth $194,603,000 after buying an additional 297,299 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Neurocrine Biosciences by 3.4% during the first quarter. Geode Capital Management LLC now owns 1,435,737 shares of the company's stock worth $145,127,000 after acquiring an additional 47,042 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.